ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 0774 • ACR Convergence 2020

    Nr4a1-high Arthritogenic T Cells from SKG Mice Are Associated with Markers of Recent and Chronic Antigen-stimulation and an Altered T Cell Receptor Repertoire

    Judith Ashouri-Sinha1, Elizabeth McCarthy1, Steven Yu2, Chun Jimmie Ye1 and Arthur Weiss1, 1UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, San Francisco, CA, 2UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, San Francsico, CA

    Background/Purpose: T cells can either be activated through their T cell receptor (TCR) in an antigen-specific manner, or in response to cytokines. Identification of antigen-reactive…
  • Abstract Number: 1040 • ACR Convergence 2020

    Clinical Characteristics of Sarcoidosis in Asian Population: A 14-year Single Center Retrospective Cohort Study from Thailand

    Athiwat Tripipitsiriwat1, Chulaluk Komoltri1, Ruchira Ruangchira-Urai1 and Patompong Ungprasert2, 1Mahidol University, Bangkok, Thailand, 2Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH

    Background/Purpose: Data on clinical manifestations of Asians with sarcoidosis are still relatively limited and most of the previously published studies are from East Asia. This…
  • Abstract Number: 1193 • ACR Convergence 2020

    Unsupervised Molecular Profile Clustering in the Serum of Rheumatoid Arthritis Patients Identifies Groups with Differential CV-risk SCORE: Modulation by Biological Therapies

    Maria Luque-Tevar1, Carlos Pérez-Sánchez1, Pilar Font2, Alejandra Maria Patiño-Trives1, Montserrat Romero-Gomez2, Desirée Ruiz-Vilchez2, Sara Remuzgo-Martínez3, Raquel López-Mejías4, Iván Arias de la Rosa1, Carmen Torres-Granados1, María-Carmen Abalos-Aguilera1, Rafaela Ortega-Castro2, Alejandro Escudero-Contreras2, Carlos Rodriguez-Escalera5, Jose Perez-Venegas6, Mª Dolores Ruiz-Montesinos6, Carmen Dominguez6, Carmen Romero-Barco7, Antonio Fernandez-Nebro8, Natalia Mena-Vazquez9, Jose Luis Marenco10, Julia Uceda-Montañez10, Mª Dolores Toledo-Coello11, Nuria Barbarroja1, M Angeles Aguirre2, Eduardo Collantes2, Miguel A Gonzalez-Gay12 and Chary Lopez-Pedrera1, 1Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, 2Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, 3Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Santander, Spain, 4Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 5Hospital Universitario de Jaen, Jaén, Spain, 6Hospital Universitario Virgen Macarena, Sevilla, Sevilla, Spain, 7Hospital Clínico Universitario, Málaga, Málaga, Spain, 8University of Malaga, Malaga, Spain, 9Hospital Regional Universitario de Málaga, Málaga, Spain, 10Hospital Universitario Virgen de Valme, Sevilla, Sevilla, Spain, 11Hospital Universitario de Jerez de la Frontera, Cádiz, Spain, Cádiz, Spain, 12Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander

    Background/Purpose: To identify specific molecular profiles associated to the enhanced cardiovascular (CV)-risk present in Rheumatoid Arthritis (RA) patients and their modulation by biologic disease modifying…
  • Abstract Number: 1412 • ACR Convergence 2020

    A T Cell Intrinsic Role for Nod2 in Suppression of Th17-Mediated Experimental Arthritis and Uveitis: Implications for Blau Syndrome

    Ruth Napier1, Ellen Lee1, Emily Vance1, Sydney Lashley2, Luke Uebelhoer3, Christina Lancioni3, Richard Vehe4, Bryce Binstadt4, Rachel Caspi5 and Holly Rosenzweig1, 1Oregon Health & Science University and VA Portland Health Care System, Portland, OR, 2VA Portland Health Care System, Portland, OR, 3Oregon Health & Science University, Portland, 4University of Minnesota, Minneapolis, MN, 5NIH, Bethesda, MD

    Background/Purpose: Mutations in nucleotide-binding oligomerization domain-containing protein 2 (NOD2) cause Blau syndrome, an inflammatory disorder characterized by uveitis, dermatitis, and polyarthritis. The antimicrobial functions of NOD2 are…
  • Abstract Number: 1577 • ACR Convergence 2020

    Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis

    Jeffrey Sarazin1, Ann Impens2, Nada Abdulaziz1, Stacey Anderson3, Leslie Fecher1, Christopher Lao1 and Elena Schiopu1, 1Michigan Medicine, Ann Arbor, MI, 2Midwestern University, Ann Arbor, IL, 3University of Michigan, Ann Arbor, MI

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as a paradigm shift in the treatment of malignancies, but can have significant side effects, termed immune related…
  • Abstract Number: 1949 • ACR Convergence 2020

    CB2 Receptor Distribution and Effects of LenabasumTM in Dermatomyositis In Vitro

    Spandana Maddukuri1, Jay Patel2, Christina Bax3, Maria Wysocka3 and Victoria Werth4, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, 3University of Pennsylvania, Department of Dermatology, Philadelphia, 4University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia

    Background/Purpose: Dermatomyositis (DM) patients report poor quality of life due to disease activity and persistent itch. Lenabasum is an oral non-immunosuppressive, non-psychoactive cannabinoid type 2…
  • Abstract Number: 0001 • ACR Convergence 2020

    Management of Rheumatic Diseases During COVID-19: A National Veterans Affairs Survey of Rheumatologists

    Jasvinder Singh1, John Richards2, Elizabeth Chang3, Amy Joseph4 and Bernard Ng5, 1University of Alabama at Birmingham, Birmingham, AL, 2Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 3PVAHCS, Phoenix, AZ, 4Washington University / St. Louis VA, Saint Louis, MO, 5VA Puget Sound HCS, Seattle, WA

    Background/Purpose: To assess the experience, views and opinions of rheumatology providers at Veterans Affairs (VA) facilities about rheumatic disease healthcare issues during the COVID-19 pandemic.Methods:…
  • Abstract Number: 0287 • ACR Convergence 2020

    RNA Externalized by Neutrophil Extracellular Traps Promotes Inflammatory Pathways in Endothelial Cells

    Xinghao Wang1, Philip Carlucci2, Jorge Romo-Tena1, Jose Torres-Ruiz1, Hong-Wei Sun1, Markus Hafner1, Mariana Kaplan3 and Luz Blanco4, 1NIAMS, National Institute of Health, Bethesda, 2New York University School of Medicine, New York, NY, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville

    Background/Purpose: Neutrophil extracellular traps (NETs) are extracellular lattices composed of nucleic material bound to neutrophil granule proteins. NETs may play pathogenic roles in development and…
  • Abstract Number: 0538 • ACR Convergence 2020

    Autoimmune Disease Outcomes of Women with Breast Implants: A Population-Based Study

    Madeline Peterson1, Thomas O'Byrne1, John Davis1, Vanessa Kronzer1, Lynne Peterson1, Michael Weisman2 and Cynthia Crowson3, 1Mayo Clinic, Rochester, MN, 2Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, LOS ANGELES, CA, 3Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN

    Background/Purpose: The long-term safety of breast implants has been a debated topic; two recent studies have raised new concerns about their potential negative health effects…
  • Abstract Number: 0800 • ACR Convergence 2020

    A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis

    Jonathan Kay1, Janusz Jaworski2, Rafal Wojciechowski3, Piotr Wiland4, Anna Dudek5, Marek Krogulec6, Slawomir Jeka7, Agnieszka Zielinska8, Jakub Trefler9, Katarzyna Bartnicka-Maslowska10, Magdalena Krajewska-Wlodarczyk11, Piotr Klimiuk12, Daniel Furst*13, SangJoon Lee14, YunJu Bae14, GoEun Yang14, JaeKyoung Yoo14, HyunJin Lee14 and Edward C Keystone15, 1University of Massachusetts Medical School, Worcester, MA, 2Reumatika-Centrum Reumatologii, Warsaw, Poland, 3University Hospital No 2, Bydgoszcz, Poland, 4Medical Univeristy, Wroclaw, Poland, 5Centrum Medyczne AMED, Warsaw, Poland, 6Rheumatology Clinic NZOZ Lecznica MAK-MED, Nadarzyn, Poland, 72nd Univ Hospital, CM UMK, Bydgoszcz, Poland, 8Medycyna Kliniczna Marzena Waszczak-Jeka, Warsaw, Poland, 9Reuma Centrum, Warsaw, Poland, 10Centrum Medyczne AMED oddzial w Łodzi, Łódź, Poland, 11University of Warmia and Mazury, Olsztyn, Poland, 12Medical University of Białystok and Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Białystok, Poland, 13Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, 14Celltrion, Inc., Incheon, Republic of Korea, 15Mount Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: CT-P17 (100 mg/mL) is the first proposed biosimilar of the high concentration and citrate-free formulation of reference adalimumab. The purpose of this study was…
  • Abstract Number: 1043 • ACR Convergence 2020

    Ocular Scleral Pathology and Immune-Mediated Inflammatory Diseases. Study of 170 Patients from a Single Universitary Center

    Lara Sanchez-Bilbao1, Inigo Gonzalez-Mazon2, José Luis Martín-Varillas3, David Martinez-Lopez4, Carmen Alvarez-Reguera1, Alba Herrero Morant1, Rosalia Demetrio-Pablo1, Vanesa Calvo-Río1, Miguel Ángel González-Gay5 and Ricardo Blanco1, 1Hospital Universitario Marques de Valdecilla, Santander, Spain, 2Hospital Universitario Marques de Valdecilla, Bezana, Spain, 3Hospital Sierrallana, Torrelavega, Spain, 4Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, 5Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Ocular scleral pathology (OSP) includes episcleritis and scleritis. Episcleritis is generally a benign disease with a self-limited course, while scleritis is a more severe…
  • Abstract Number: 1261 • ACR Convergence 2020

    Antiphospholipid Patterns Predict the Risk of Thrombosis in Systemic Lupus Erythematosus

    Selcan Demir1, Jessica Li2, Laurence Magder3 and Michelle Petri4, 1Hacettepe University Faculty of Medicine, Ankara, Ankara, Turkey, 2Johns Hopkins University, Baltimore, MD, 3University of Maryland, Baltimore, Baltimore, MD, 4Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Antiphospholipid syndrome (APS) has been classified as the development of venous and/or arterial thromboses, and/or pregnancy morbidity, in the presence of persistently raised levels…
  • Abstract Number: 1415 • ACR Convergence 2020

    Murine Roseolovirus Induces Autoimmune Disease and Development of Autoreactive T Cells and Autoantibodies

    Tarin Bigley1, Jose Saenz2, Li-Ping Yang2, Jason Mills2 and Wayne Yokoyama2, 1Washington University in St. Louis, Saint Louis, MO, 2Washington University in St. Louis, St. Louis, MO

    Background/Purpose: Murine roseolovirus (MRV) is a recently sequenced beta-herpesvirus that is a natural murine pathogen and is genetically highly related to HHV6 and HHV7. The…
  • Abstract Number: 1578 • ACR Convergence 2020

    Rituximab Hypersensitivity in Rheumatic and Inflammatory Diseases: Role of Skin Testing

    Sravani Penumarty1, Javier Quintero Betancourt2, Eugenio Capitle2 and Reena Khianey2, 1Rutgers, Eastvale, CA, 2Rutgers, Newark, NJ

    Background/Purpose: Infusion-related reactions have been reported with rituximab, a monoclonal antibody targeting the CD20 antigen on B cells, and may result in discontinuation of the…
  • Abstract Number: 2037 • ACR Convergence 2020

    Geographic Distribution and Environmental Triggers of Systemic Sclerosis in Massachusetts

    Anastasiya Muntyanu1, Bina Kassamali2, Ruth Ann Vleugels3 and Avery LaChance3, 1McGill University, Montreal, QC, Canada, 2Harvard Medical School, Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune sclerosing disease with a 10-year survival rate of less than 65%. This rate has remained unchanged for…
  • « Previous Page
  • 1
  • …
  • 64
  • 65
  • 66
  • 67
  • 68
  • …
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology